Advertisement

Sinn und Unsinn von Therapiekombinationen beim fortgeschrittenen Prostatakarzinom

  • K. Burk
  • D. Jonas

Zusammenfassung

Seit Ende des letzten Jahrhunderts ist die Androgenabhängigkeit der Prostata bekannt. White berichtete erstmals 1895 über die Beseitigung der subvesikalen Obstruktion, hervorgerufen durch das Blasenhalsadenom, mittels bilateraler Orchiektomie. Ein Jahr später hat Cabot die Beobachtung Whites, daß die Größe des Blasenhalsadenoms durch beidseitige Orchiektomie zu vermindern ist, bestätigt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bartsch W et al. (1977) Sex hormone binding globulin binding capacity, testosterone, 5-α- dihydrotestosterone, oestradiol and prolactin in plasma of patients with prostatic carcinoma under various types of hormonal treatment. Acta Endocrinol 85: 650PubMedGoogle Scholar
  2. Burk K et al. (1986) Chemotherapy of hormoneresistant prostatic carcinoma. In: Murhy G Prostate Cancer. Alan Liss, New York (in press)Google Scholar
  3. Byar DP (1973) The veterans administration cooperative urological research group’s studies of cancer of the prostate. Cancer 32: 1126–1130PubMedCrossRefGoogle Scholar
  4. Cabot AT (1896) The question of castration for enlarged prostate. Ann Surg 24: 265PubMedCrossRefGoogle Scholar
  5. Huggins C, Hodges CV (1941) Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1: 293Google Scholar
  6. Isaacs JT (1986) New principles in the management of metastatic prostatic cancer. In: Das Prostatakarzinom zwischen Hormontherapie und Zytostase. Medical trends. Solingen. S 5–27Google Scholar
  7. Labrie F et al. (1985) Complete androgen blockade at start of treatment causes a dramatic improvement of survival in advanced prostate cancer. In: A new approach to the treatment of prostatic cancer. Excerpta Medica. S 59–70Google Scholar
  8. Murphy GP et al. (1986) Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 28: 36–40PubMedCrossRefGoogle Scholar
  9. Nesbit RM, Baum WC (1950) Endocrine control of prostatic carcinoma: clinical and statistical survey of 1818 cases. JAMA 143: 1317–1320CrossRefGoogle Scholar
  10. Neumann F (1982) Different principles of androgen deprivation for palliative treatment of prostatic cancer. In: Androgens and Antiandrogens. International Symposium, Utrecht, 1982 pp 97–111Google Scholar
  11. White JW (1895) The results of double castration in hypertrophy of the prostate. Trans Amer Surg Ass 22: 103Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • K. Burk
  • D. Jonas

There are no affiliations available

Personalised recommendations